Therefore, a comprehensive understanding of the interplay among cells within TME, especially immune cells, is one of the fundamental steps to establish a drug guidance system for anti-PD-1/PD-L1 therapies in HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.